Completing its second Indian deal this quarter, Pieris AG entered a pact with Stelis Biopharma Pvt. Ltd., a subsidiary of Bangalore-based Strides Arcolab Ltd., to develop two anticalin-based protein drugs, primarily for ophthalmology indications.